CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PSMD12 (ImmuneEditome ID:5718)

1. Gene summary of enriched editing regions for PSMD12

check button Gene summary
Gene informationGene symbol

PSMD12

Gene ID

5718

GeneSynonymsRpn5|STISS|p55
GeneCytomap

17q24.2

GeneTypeprotein-coding
GeneDescription26S proteasome non-ATPase regulatory subunit 12|26S proteasome regulatory subunit RPN5|26S proteasome regulatory subunit p55|proteasome (prosome, macropain) 26S subunit, non-ATPase, 12
GeneModificationdate20230517
UniprotIDA0A0S2Z489;O00232;J3KTJ5;J3KSK1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:67338561-67339424:-ENST00000356126.6ENSG00000197170.8PSMD12UTR3AluSq,AluSxchr17:67338561-67339424:-.alignment
chr17:67351965-67352286:-ENST00000581618.1ENSG00000197170.8PSMD12ncRNA_intronicAluSc,AluJrchr17:67351965-67352286:-.alignment
chr17:67351965-67352286:-ENST00000584289.4ENSG00000197170.8PSMD12ncRNA_intronicAluSc,AluJrchr17:67351965-67352286:-.alignment
chr17:67354238-67355405:-ENST00000581618.1ENSG00000197170.8PSMD12ncRNA_exonicAluSx1,AluJo,AluSzchr17:67354238-67355405:-.alignment
chr17:67358011-67358399:-ENST00000578015.1ENSG00000197170.8PSMD12ncRNA_intronicCharlie19a,AluSz,AluJbchr17:67358011-67358399:-.alignment
chr17:67358011-67358399:-ENST00000581618.1ENSG00000197170.8PSMD12ncRNA_intronicCharlie19a,AluSz,AluJbchr17:67358011-67358399:-.alignment
chr17:67358011-67358399:-ENST00000584289.4ENSG00000197170.8PSMD12ncRNA_intronicCharlie19a,AluSz,AluJbchr17:67358011-67358399:-.alignment


Top

2. Tumor-specific enriched editing regions for PSMD12


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr17:67338561-67339424:-BRCAEER1.3370e-19image
ENSG00000197170.8,PSMD12BRCAEAG7.7607e-20image
chr17:67338561-67339424:-HNSCEER1.9722e-08image
ENSG00000197170.8,PSMD12HNSCEAG1.9722e-08image
chr17:67338561-67339424:-KIRCEER2.9072e-06image
ENSG00000197170.8,PSMD12KIRCEAG2.1102e-06image
chr17:67338561-67339424:-KIRPEER1.7877e-04image
ENSG00000197170.8,PSMD12KIRPEAG1.7081e-04image
chr17:67338561-67339424:-LUADEER1.4319e-04image
ENSG00000197170.8,PSMD12LUADEAG7.4540e-05image
chr17:67338561-67339424:-LUSCEER1.3837e-02image
ENSG00000197170.8,PSMD12LUSCEAG1.1928e-02image
chr17:67338561-67339424:-PRADEER6.9802e-10image
ENSG00000197170.8,PSMD12PRADEAG6.5289e-10image
chr17:67338561-67339424:-THCAEER4.9616e-02image
ENSG00000197170.8,PSMD12THCAEAG4.8739e-02image
chr17:67338561-67339424:-UCECEER1.7996e-04image
ENSG00000197170.8,PSMD12UCECEAG1.5382e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr17:67338561-67339424:-KIRCPathEER1.7221e-023.2792e-020.0926image
ENSG00000197170.8,PSMD12KIRCPathEAG1.4689e-023.0516e-020.0939image
chr17:67338561-67339424:-LIHCPathEER1.2245e-024.3883e-02-0.1095image
ENSG00000197170.8,PSMD12LIHCPathEAG1.2220e-024.3737e-02-0.1096image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000197170.8,PSMD12BLCAEAG2.7214e-023.7963e-021.2092e+01image
chr17:67354238-67355405:-ESCAEER4.7090e-022.6601e-023.6578e+03image
chr17:67338561-67339424:-LGGEER4.7602e-027.7171e-038.1036e+02image
ENSG00000197170.8,PSMD12LGGEAG4.7602e-027.7171e-038.1036e+02image
chr17:67338561-67339424:-UCSEER3.2933e-022.2652e-022.3245e+04image
ENSG00000197170.8,PSMD12UCSEAG3.2933e-021.7266e-022.9738e+04image

Top

3. Enriched editing regions and immune related genes for PSMD12


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:67338561-67339424:-COADEERENSG00000240974,CTD-2024I7.10.19936.9478e-031.6250e-130.4297imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr17:67338561-67339424:-COADEERENSG00000147459,DOCK50.18542.9793e-023.5906e-170.4836imageNNDOCK5EosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr17:67338561-67339424:-COADEERENSG00000201208,Y_RNA0.17903.6294e-024.5760e-200.5204imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr17:67338561-67339424:-COADEERENSG00000141664,ZCCHC20.17674.7297e-024.5152e-120.4055imageNNNANeutrophilsGSVA_HALLMARK_PEROXISOME
chr17:67338561-67339424:-HNSCEERENSG00000228499,TMSB10P10.30731.0601e-099.7944e-240.4312imageNNNAT_cells_CD8GSVA_HALLMARK_HEME_METABOLISM
chr17:67338561-67339424:-HNSCEERENSG00000148450,MSRB20.25279.2536e-072.0000e-200.4006imageNNNAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
chr17:67338561-67339424:-HNSCEERENSG00000116691,MIIP0.18366.5592e-045.0572e-210.4063imageNNNANK_cells_activatedGSVA_HALLMARK_UV_RESPONSE_DN
chr17:67338561-67339424:-HNSCEERENSG00000175756,AURKAIP10.17621.2544e-035.6531e-210.4059imageNNNANK_cells_activatedGSVA_HALLMARK_UV_RESPONSE_DN
chr17:67338561-67339424:-HNSCEERENSG00000252147,RNY3P160.16442.5558e-031.0950e-270.4640imageNNNANK_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr17:67338561-67339424:-HNSCEERENSG00000148291,SURF20.15853.8670e-031.3385e-200.4023imageNNNAT_cells_CD8GSVA_HALLMARK_UV_RESPONSE_DN

More results



Top

4. Enriched editing regions and immune related splicing for PSMD12


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:67338561-67339424:-
BLCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.48814.2816e-198.3714e-19-0.4231imageNNPRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000197170.8,PSMD12
COADEAGIRENSG00000060237.12chr12879572:880999:881691:8817890.18644.1432e-021.2503e-220.6262imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184WNK1EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197170.8,PSMD12
COADEAGIRENSG00000100813.10chr1423068362:23069617:23071124:230711860.20734.8366e-024.2847e-280.6263imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184ACIN1Mast_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000197170.8,PSMD12
COADEAGIRENSG00000138031.10chr224826044:24826126:24827545:248276080.23652.1648e-023.3801e-210.5328imageNACIN1;ADAR;AIFM1;AUH;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000197170.8,PSMD12
COADEAGIRENSG00000108669.12chr1778674047:78676169:78680189:786802180.22683.4406e-021.0898e-230.5583imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184CYTH1EosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000197170.8,PSMD12
COADEAGIRENSG00000046651.10chrX13768717:13768785:13769065:137691710.23062.7573e-021.1400e-120.4151imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;YWHAG;ZC3H7B;ZNF184NANeutrophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197170.8,PSMD12
COADEAGA3ENSG00000205531.8chr112951258:2951295:2944436:2945646:2944436:2949264-0.22633.4686e-029.9267e-13-0.4161imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NANeutrophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197170.8,PSMD12
COADEAGIRENSG00000058673.11chr1203795659:203795794:203801574:2038022610.26331.2187e-031.2825e-180.5425imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NAEosinophilsGSVA_HALLMARK_PEROXISOME
ENSG00000197170.8,PSMD12
COADEAGIRENSG00000109180.10chr448831083:48831496:48832619:488326630.21604.9203e-029.3134e-240.5616imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197170.8,PSMD12
COADEAGMEXENSG00000138041.11chr255568193:55568363:55573618:55573777:55579678:55579781:55581566:55581698-0.22563.4909e-022.4658e-23-0.5554imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for PSMD12


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:67338561-67339424:-ACCEERNK_cells_resting1.5669e-020.2728image
ENSG00000197170.8,PSMD12ACCEAGNK_cells_resting1.5669e-020.2728image
chr17:67338561-67339424:-BLCAEERMacrophages_M11.1323e-060.2402image
ENSG00000197170.8,PSMD12BLCAEAGMacrophages_M12.3955e-050.2090image
chr17:67338561-67339424:-BRCAEERNK_cells_activated1.1774e-030.0987image
ENSG00000197170.8,PSMD12BRCAEAGNK_cells_activated1.2079e-030.0985image
chr17:67338561-67339424:-CESCEERMonocytes7.7179e-040.1931image
ENSG00000197170.8,PSMD12CESCEAGMonocytes7.7418e-040.1931image
chr17:67338561-67339424:-CHOLEERT_cells_CD4_naive7.4807e-030.4444image
ENSG00000197170.8,PSMD12CHOLEAGT_cells_CD4_naive7.4807e-030.4444image
chr17:67338561-67339424:-COADEERNK_cells_resting2.8934e-020.1332image
ENSG00000197170.8,PSMD12COADEAGEosinophils3.0245e-060.2788image
chr17:67338561-67339424:-ESCAEERMonocytes5.1816e-03-0.2193image
chr17:67354238-67355405:-ESCAEERNK_cells_activated2.5634e-020.4974image
ENSG00000197170.8,PSMD12ESCAEAGMonocytes4.2061e-03-0.2244image
chr17:67338561-67339424:-GBMEERMacrophages_M02.8755e-04-0.2780image
ENSG00000197170.8,PSMD12GBMEAGMacrophages_M03.0398e-04-0.2769image
chr17:67338561-67339424:-HNSCEERMacrophages_M15.6543e-030.1245image
ENSG00000197170.8,PSMD12HNSCEAGMacrophages_M15.6543e-030.1245image
chr17:67338561-67339424:-KICHEERMacrophages_M01.3865e-020.3039image
ENSG00000197170.8,PSMD12KICHEAGMacrophages_M01.3865e-020.3039image
chr17:67338561-67339424:-KIRCEERMonocytes7.6011e-03-0.1360image
ENSG00000197170.8,PSMD12KIRCEAGMonocytes5.9601e-03-0.1401image
chr17:67338561-67339424:-KIRPEERNK_cells_resting5.2174e-030.1653image
ENSG00000197170.8,PSMD12KIRPEAGNK_cells_resting5.0899e-030.1658image
chr17:67358011-67358399:-LAMLEERT_cells_follicular_helper2.9277e-020.3252image
chr17:67338561-67339424:-LGGEERNeutrophils5.4337e-04-0.1500image
ENSG00000197170.8,PSMD12LGGEAGNeutrophils5.4337e-04-0.1500image
chr17:67338561-67339424:-LIHCEERMacrophages_M11.2407e-020.1313image
ENSG00000197170.8,PSMD12LIHCEAGMacrophages_M11.2448e-020.1312image
chr17:67338561-67339424:-LUADEERT_cells_gamma_delta3.8942e-040.1572image
ENSG00000197170.8,PSMD12LUADEAGT_cells_gamma_delta6.7791e-040.1503image
chr17:67338561-67339424:-LUSCEERT_cells_CD4_memory_activated2.6651e-030.1349image
ENSG00000197170.8,PSMD12LUSCEAGT_cells_CD4_memory_activated3.4552e-030.1313image
chr17:67338561-67339424:-MESOEERT_cells_follicular_helper2.7603e-020.2448image
ENSG00000197170.8,PSMD12MESOEAGT_cells_follicular_helper2.7603e-020.2448image
chr17:67338561-67339424:-OVEERT_cells_CD84.5881e-050.2365image
ENSG00000197170.8,PSMD12OVEAGT_cells_CD84.8558e-050.2358image
chr17:67338561-67339424:-PAADEERT_cells_gamma_delta4.8050e-020.1497image
ENSG00000197170.8,PSMD12PAADEAGT_cells_gamma_delta4.8050e-020.1497image
chr17:67338561-67339424:-PCPGEERPlasma_cells1.6507e-020.1785image
ENSG00000197170.8,PSMD12PCPGEAGPlasma_cells1.6507e-020.1785image
chr17:67338561-67339424:-PRADEERT_cells_CD4_naive1.5524e-020.1085image
ENSG00000197170.8,PSMD12PRADEAGT_cells_CD4_naive1.5810e-020.1082image
chr17:67338561-67339424:-SARCEERT_cells_regulatory_(Tregs)4.0920e-030.1792image
ENSG00000197170.8,PSMD12SARCEAGT_cells_regulatory_(Tregs)4.0920e-030.1792image
chr17:67338561-67339424:-SKCMEERT_cells_CD86.2980e-040.1606image
ENSG00000197170.8,PSMD12SKCMEAGT_cells_CD86.2980e-040.1606image
chr17:67338561-67339424:-STADEERMacrophages_M21.9738e-030.1648image
ENSG00000197170.8,PSMD12STADEAGMacrophages_M21.6369e-030.1677image
chr17:67338561-67339424:-TGCTEERNeutrophils3.2175e-040.2879image
ENSG00000197170.8,PSMD12TGCTEAGNeutrophils3.0392e-040.2891image
chr17:67338561-67339424:-THCAEERPlasma_cells2.9048e-120.3049image
ENSG00000197170.8,PSMD12THCAEAGPlasma_cells3.8908e-120.3032image
chr17:67338561-67339424:-THYMEERNK_cells_resting7.5140e-030.2547image
ENSG00000197170.8,PSMD12THYMEAGNK_cells_resting7.5140e-030.2547image
chr17:67338561-67339424:-UCECEERB_cells_naive3.8677e-02-0.1597image
chr17:67338561-67339424:-UCSEERB_cells_naive2.4385e-03-0.3972image
ENSG00000197170.8,PSMD12UCSEAGB_cells_naive2.2829e-03-0.3996image
chr17:67338561-67339424:-UVMEERT_cells_CD4_naive8.6777e-030.3445image
ENSG00000197170.8,PSMD12UVMEAGT_cells_CD4_naive8.6777e-030.3445image


Top

6. Enriched editing regions and immune gene sets for PSMD12


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000197170.8,PSMD12CHOLEAG1.4698e-02-0.40902.0699e-02-0.38962.2000e-02-0.38601.2665e-02-0.4171image
chr17:67338561-67339424:-CHOLEER1.4698e-02-0.40902.0699e-02-0.38962.2000e-02-0.38601.2665e-02-0.4171image
ENSG00000197170.8,PSMD12KICHEAG3.9953e-02-0.25551.7527e-02-0.29384.1025e-03-0.35141.2593e-02-0.3079image
chr17:67338561-67339424:-KICHEER3.9953e-02-0.25551.7527e-02-0.29384.1025e-03-0.35141.2593e-02-0.3079image
chr17:67338561-67339424:-LUADEER4.5676e-050.18042.1566e-040.16394.5620e-040.15543.9989e-050.1817image
ENSG00000197170.8,PSMD12LUADEAG1.7755e-040.16561.8669e-040.16501.0380e-030.14511.2408e-030.1429image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr17:67338561-67339424:-BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.8570e-070.2568image
ENSG00000197170.8,PSMD12BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.2564e-050.2056image
chr17:67338561-67339424:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8184e-200.2773image
ENSG00000197170.8,PSMD12BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.4281e-190.2672image
chr17:67338561-67339424:-CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.9538e-080.3172image
ENSG00000197170.8,PSMD12CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.8541e-080.3176image
ENSG00000197170.8,PSMD12CHOLGSVA_HALLMARK_HEME_METABOLISMEAG1.7531e-03-0.5099image
chr17:67338561-67339424:-CHOLGSVA_HALLMARK_HEME_METABOLISMEER1.7531e-03-0.5099image
ENSG00000197170.8,PSMD12COADGSVA_HALLMARK_PEROXISOMEEAG2.4389e-08-0.3302image
chr17:67338561-67339424:-COADGSVA_HALLMARK_PEROXISOMEEER7.5901e-05-0.2389image
chr17:67338561-67339424:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.2162e-040.2983image
ENSG00000197170.8,PSMD12ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1888e-040.2987image
chr17:67354238-67355405:-ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.1721e-020.4812image
chr17:67338561-67339424:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3269e-140.5517image
ENSG00000197170.8,PSMD12GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5778e-140.5504image
chr17:67338561-67339424:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5093e-110.2946image
ENSG00000197170.8,PSMD12HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.5093e-110.2946image
chr17:67338561-67339424:-KICHGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.0032e-04-0.4637image
ENSG00000197170.8,PSMD12KICHGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.0032e-04-0.4637image
chr17:67338561-67339424:-KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.4649e-03-0.1618image
ENSG00000197170.8,PSMD12KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.1132e-03-0.1658image
chr17:67338561-67339424:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER6.1197e-05-0.2355image
ENSG00000197170.8,PSMD12KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG5.8551e-05-0.2361image
ENSG00000197170.8,PSMD12LAMLGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.7893e-030.3051image
chr17:67338561-67339424:-LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.1371e-140.3180image
ENSG00000197170.8,PSMD12LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.1371e-140.3180image
chr17:67338561-67339424:-LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.6721e-090.3018image
ENSG00000197170.8,PSMD12LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG4.6723e-090.3018image
chr17:67338561-67339424:-LUADGSVA_HALLMARK_MTORC1_SIGNALINGEER6.3640e-070.2194image
ENSG00000197170.8,PSMD12LUADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.5710e-050.1798image
chr17:67338561-67339424:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.1928e-080.2406image
ENSG00000197170.8,PSMD12LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2826e-070.2349image
chr17:67338561-67339424:-MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER4.9383e-030.3094image
ENSG00000197170.8,PSMD12MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.9383e-030.3094image
ENSG00000197170.8,PSMD12OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.0098e-140.4258image
chr17:67338561-67339424:-OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.6225e-140.4268image
chr17:67338561-67339424:-PAADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER7.2952e-04-0.2530image
ENSG00000197170.8,PSMD12PAADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG7.2952e-04-0.2530image
chr17:67338561-67339424:-PCPGGSVA_HALLMARK_ANDROGEN_RESPONSEEER7.6722e-04-0.2486image
ENSG00000197170.8,PSMD12PCPGGSVA_HALLMARK_ANDROGEN_RESPONSEEAG7.6722e-04-0.2486image
ENSG00000197170.8,PSMD12PRADGSVA_HALLMARK_HEME_METABOLISMEAG8.4348e-07-0.2188image
chr17:67338561-67339424:-PRADGSVA_HALLMARK_HEME_METABOLISMEER1.2012e-06-0.2158image
chr17:67338561-67339424:-READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.1974e-030.3292image
ENSG00000197170.8,PSMD12READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.1974e-030.3292image
ENSG00000197170.8,PSMD12SARCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.8671e-03-0.1860image
chr17:67338561-67339424:-SARCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.8671e-03-0.1860image
ENSG00000197170.8,PSMD12SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG7.4198e-09-0.2683image
chr17:67338561-67339424:-SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEER7.4198e-09-0.2683image
chr17:67354238-67355405:-STADGSVA_HALLMARK_MTORC1_SIGNALINGEER1.3082e-020.3187image
ENSG00000197170.8,PSMD12STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0781e-060.2572image
chr17:67338561-67339424:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.3772e-060.2491image
ENSG00000197170.8,PSMD12TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.9478e-05-0.3389image
chr17:67338561-67339424:-TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.9432e-05-0.3389image
ENSG00000197170.8,PSMD12THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.5838e-070.2314image
chr17:67338561-67339424:-THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.1572e-070.2338image
ENSG00000197170.8,PSMD12THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1148e-04-0.3617image
chr17:67338561-67339424:-THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.1148e-04-0.3617image
ENSG00000197170.8,PSMD12UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.0135e-04-0.2822image
chr17:67338561-67339424:-UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER5.0581e-05-0.3074image
ENSG00000197170.8,PSMD12UCSGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG9.4033e-040.4300image
chr17:67338561-67339424:-UCSGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.1828e-030.4224image
chr17:67338561-67339424:-UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEER7.7142e-040.4328image
ENSG00000197170.8,PSMD12UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG7.7142e-040.4328image


Top

7. Enriched editing regions and drugs for PSMD12


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr17:67338561-67339424:-BLCACGP.60474EER6.5577e-08-0.2658image
ENSG00000197170.8,PSMD12BLCAFH535EAG1.0195e-060.2409image
chr17:67338561-67339424:-BRCACGP.082996EER7.5608e-05-0.1203image
ENSG00000197170.8,PSMD12BRCACisplatinEAG7.8422e-05-0.1200image
chr17:67338561-67339424:-CESCCGP.60474EER1.1229e-05-0.2506image
ENSG00000197170.8,PSMD12CESCCGP.60474EAG1.1635e-05-0.2501image
ENSG00000197170.8,PSMD12CHOLGDC.0449EAG1.2873e-02-0.4163image
chr17:67338561-67339424:-CHOLGDC.0449EER1.2873e-02-0.4163image
ENSG00000197170.8,PSMD12COADCCT007093EAG1.0163e-09-0.3595image
chr17:67338561-67339424:-COADMG.132EER8.7388e-040.2018image
chr17:67354238-67355405:-ESCACCT018159EER4.4496e-040.7107image
chr17:67338561-67339424:-ESCACGP.60474EER3.3996e-04-0.2789image
ENSG00000197170.8,PSMD12ESCACGP.60474EAG2.9660e-04-0.2816image
ENSG00000197170.8,PSMD12GBMBIBW2992EAG1.0077e-11-0.4966image
chr17:67338561-67339424:-GBMBIBW2992EER9.2298e-12-0.4974image
chr17:67338561-67339424:-HNSCDocetaxelEER9.6020e-14-0.3269image
ENSG00000197170.8,PSMD12HNSCDocetaxelEAG9.6020e-14-0.3269image
chr17:67338561-67339424:-KICHEmbelinEER1.8417e-030.3792image
ENSG00000197170.8,PSMD12KICHEmbelinEAG1.8417e-030.3792image
ENSG00000197170.8,PSMD12KIRCEmbelinEAG7.6755e-040.1710image
chr17:67338561-67339424:-KIRCEmbelinEER1.0664e-030.1664image
chr17:67338561-67339424:-KIRPDasatinibEER1.6931e-05-0.2544image
ENSG00000197170.8,PSMD12KIRPDasatinibEAG1.9306e-05-0.2528image
ENSG00000197170.8,PSMD12LAMLCHIR.99021EAG2.8822e-02-0.2256image
chr17:67354238-67355405:-LAMLMidostaurinEER3.5095e-02-0.2599image
chr17:67358011-67358399:-LAMLAZD8055EER3.2117e-02-0.3200image
chr17:67338561-67339424:-LGGBexaroteneEER2.0785e-15-0.3361image
ENSG00000197170.8,PSMD12LGGBexaroteneEAG2.0785e-15-0.3361image
ENSG00000197170.8,PSMD12LIHCFTI.277EAG7.5118e-120.3497image
chr17:67338561-67339424:-LIHCFTI.277EER7.5226e-120.3497image
ENSG00000197170.8,PSMD12LUADGemcitabineEAG1.9987e-04-0.1643image
chr17:67338561-67339424:-LUADCGP.60474EER4.3968e-05-0.1807image
ENSG00000197170.8,PSMD12LUSCGDC.0449EAG1.1856e-04-0.1723image
chr17:67338561-67339424:-LUSCGDC.0449EER1.1930e-04-0.1723image
chr17:67338561-67339424:-MESOCGP.082996EER1.0479e-02-0.2830image
ENSG00000197170.8,PSMD12MESOCGP.082996EAG1.0479e-02-0.2830image
ENSG00000197170.8,PSMD12OVCGP.60474EAG1.3073e-04-0.2224image
chr17:67338561-67339424:-OVCGP.60474EER1.0959e-04-0.2248image
ENSG00000197170.8,PSMD12PAADAxitinibEAG4.0075e-040.2669image
chr17:67338561-67339424:-PAADAxitinibEER4.0075e-040.2669image
ENSG00000197170.8,PSMD12PCPGBMS.536924EAG1.6789e-04-0.2776image
chr17:67338561-67339424:-PCPGBMS.536924EER1.6789e-04-0.2776image
ENSG00000197170.8,PSMD12PRADEmbelinEAG3.0934e-060.2075image
chr17:67338561-67339424:-PRADEmbelinEER2.3318e-060.2100image
ENSG00000197170.8,PSMD12READGSK269962AEAG1.3370e-03-0.3261image
chr17:67338561-67339424:-READGSK269962AEER1.3370e-03-0.3261image
ENSG00000197170.8,PSMD12SARCCisplatinEAG1.9525e-07-0.3189image
chr17:67338561-67339424:-SARCCisplatinEER1.9525e-07-0.3189image
ENSG00000197170.8,PSMD12SKCMAZD6244EAG2.0838e-07-0.2418image
chr17:67338561-67339424:-SKCMAZD6244EER2.0838e-07-0.2418image
chr17:67354238-67355405:-STADImatinibEER4.8589e-030.3589image
ENSG00000197170.8,PSMD12STADBMS.509744EAG9.4077e-07-0.2586image
chr17:67338561-67339424:-STADBMS.509744EER1.0347e-06-0.2576image
chr17:67338561-67339424:-TGCTEmbelinEER2.0335e-050.3382image
ENSG00000197170.8,PSMD12TGCTEmbelinEAG2.0480e-050.3381image
ENSG00000197170.8,PSMD12THCAEmbelinEAG1.0333e-260.4525image
chr17:67338561-67339424:-THCAEmbelinEER1.0199e-260.4526image
ENSG00000197170.8,PSMD12THYMDMOGEAG1.6998e-040.3526image
chr17:67338561-67339424:-THYMDMOGEER1.6998e-040.3526image
chr17:67338561-67339424:-UCECLenalidomideEER5.1022e-07-0.3760image
ENSG00000197170.8,PSMD12UCECABT.888EAG5.3589e-07-0.3743image
chr17:67338561-67339424:-UCSEmbelinEER2.0765e-060.5861image
ENSG00000197170.8,PSMD12UCSEmbelinEAG2.2794e-060.5842image
ENSG00000197170.8,PSMD12UVMBexaroteneEAG3.3326e-04-0.4586image
chr17:67338561-67339424:-UVMBexaroteneEER3.3326e-04-0.4586image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType